L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model

L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model

Epithelial ovarian cancer (EOC) is the fifth most common cancer affecting the female population. At present, different targeted treatment approaches may improve currently employed therapies leading either to the delay of tumor recurrence or to disease stabilization. In this study we show that syndec...

Full description

Bibliographic Details
Main Authors: Paola Orecchia, Enrica Balza, Gabriella Pietra, Romana Conte, Nicolò Bizzarri, Simone Ferrero, Maria Cristina Mingari, Barbara Carnemolla
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cancers
Subjects:
ovarian cancer
syndecan-1 (SDC1)
46F2SIP anti-syndecan-1
L19-IL2 immunocytokine
vascular mimicry
angiogenesis
vessels normalization
targeted therapy
Online Access:https://www.mdpi.com/2072-6694/11/9/1232

Internet

https://www.mdpi.com/2072-6694/11/9/1232

Similar Items